Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, James I. Mullins, Elena E. Giorgi et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang et al.|Clinical Infectious Diseases|2024Cited by 3
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, James I. Mullins, Chivonne Moodley et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresLawrence Corey, Carolyn Williamson, Nicole Espy et al.|Carolina Digital Repository (University of North Carolina at Chapel Hill)|2025Cited by 0